Recent fentanyl exposure with precipitated withdrawal risk
Persistent vomiting requiring IV fluids
Admission indications
Severe withdrawal with complications
Refractory dehydration
Electrolyte derangements
Serious comorbidity
Significant cardiac disease
Respiratory failure risk
Suspected infection requiring IV therapy
Concurrent high risk withdrawal
Alcohol withdrawal risk
Benzodiazepine withdrawal risk
Pregnancy with moderate to severe withdrawal
Transfer indications
Need for opioid treatment program services not available
Higher level monitoring requirement
Obstetric or neonatal services requirement
Follow-up and linkage
Rapid access addiction clinic referral
Next day pathway when possible
Pharmacy led induction follow-up when available
Primary care linkage
Buprenorphine prescribing follow-up
Chronic pain coordination when relevant
Harm reduction supports
Naloxone supply
Safer use counselling
Needle and syringe program referral
Treatment
Treatment goals and principles
Primary goals
Symptom relief
Control autonomic symptoms
Control GI losses
Prevention of return to use and overdose
Initiation of medication for OUD preferred
Education on reduced tolerance after abstinence
Treatment of complications
Dehydration correction
Infection treatment when present
First line strategy for OUD and moderate to severe withdrawal
Buprenorphine or methadone recommended over alpha-2 agonist alone
Better withdrawal symptom control
Better retention in withdrawal management
Buprenorphine standard induction
Preconditions
Objective withdrawal present
COWS consistent with at least moderate severity
Last opioid timing compatible with withdrawal
Short-acting opioid elapsed interval usually adequate
Methadone or long-acting opioid needs longer interval
Avoidance of precipitated withdrawal risk
Fentanyl exposure increases risk
Partial agonist high affinity displaces full agonist
Day 1 dosing
Buprenorphine sublingual 2-4 mg initial dose
Reassess after 30-60 minutes
Additional 2-8 mg based on symptoms
Typical day 1 total 8-16 mg
Higher total sometimes required with high tolerance
Day 2 and maintenance
Total daily dose based on day 1 response
Common maintenance 12-24 mg daily
Split dosing option early
Twice daily dosing for symptom coverage
Monitoring and safety
Sedation risk increased with other CNS depressants
Alcohol
Benzodiazepines
Respiratory depression uncommon when used alone
Risk increases with polysubstance use
Evidence and guideline notes
ASAM 2020 focused update supports initiation after objective withdrawal signs
Initial dose 2-4 mg with titration in 2-8 mg increments
Buprenorphine micro-induction and special induction strategies
Indications
High fentanyl exposure with repeated precipitated withdrawal
Unable to tolerate abstinence interval
Transition from methadone when taper not feasible
Micro-induction principles
Very low dose buprenorphine while continuing full agonist briefly
Gradual receptor occupancy increase
Lower precipitated withdrawal risk
Close follow-up required
Daily contact plan
Clear escalation instructions
ED focused high dose induction considerations
Persistent moderate to severe symptoms after standard titration
Additional dosing in monitored setting
Observation for sedation and hypotension
Polysubstance use screening
Methadone pathway
Indications
Buprenorphine contraindication or failure
Patient preference with informed consent
High opioid tolerance with poor buprenorphine response
Regulatory and access constraints
Opioid treatment program requirements vary by jurisdiction
Hospital based initiation pathways depend on local policy
Withdrawal management dosing guidance
Initial dose typically 20-30 mg daily for short-acting opioid withdrawal management
Taper over approximately 6-10 days when detoxification goal
Dose increases for maintenance are slower
Increases no more than 10 mg about every 5 days based on symptoms or sedation
Safety monitoring
QT prolongation risk
Baseline ECG when feasible
Electrolyte correction
Sedation and respiratory depression risk
Higher with benzodiazepines and alcohol
Evidence and guideline notes
ASAM 2020 supports methadone for OUD with careful monitoring and individualized titration
Alpha-2 adrenergic agonists
Role
Symptom mitigation option when opioid agonist therapy declined or not available
Adjunct to opioid agonist therapy for autonomic symptoms
Lofexidine
Indication
Mitigation of opioid withdrawal symptoms in adults
Dosing
Starting dosage 0.54 mg orally four times daily
3 tablets of 0.18 mg per dose
5-6 hours between doses
Maximum total daily dose 2.88 mg
Maximum single dose 0.72 mg
Typical peak withdrawal use first 5-7 days
Treatment up to 14 days guided by symptoms
Discontinuation taper over 2-4 days
Reduce by 1 tablet per dose every 1-2 days
Dose adjustments
Hepatic impairment
Moderate impairment 0.36 mg four times daily
Severe impairment 0.18 mg four times daily
Renal impairment
eGFR 30-89.9 dose 0.36 mg four times daily
eGFR less than 30 dose 0.18 mg four times daily
Adverse effects
Hypotension and orthostasis
Bradycardia
Sedation
QT prolongation
Clonidine off-label
Typical oral dosing
0.1 mg orally every 6-8 hours as needed
Titrate based on symptoms and blood pressure
Hold parameters for hypotension and bradycardia per local protocol
Transdermal option
Patch for adherence support in selected patients
Adverse effects
Hypotension
Bradycardia
Rebound hypertension with abrupt cessation
Symptom targeted supportive medications
Fluids and electrolytes
Oral rehydration when tolerated
IV crystalloid when persistent vomiting or dehydration
Electrolyte replacement based on labs
Nausea and vomiting
Ondansetron orally or IV per local protocol
Metoclopramide alternative when appropriate
Diarrhoea
Loperamide when no infectious red flags
Avoid if concern for toxic megacolon or severe infection
Abdominal cramping
Dicyclomine when appropriate
Myalgias and arthralgias
Acetaminophen dosing per local protocol
NSAID dosing per local protocol when no contraindication
Anxiety and insomnia
Hydroxyzine as non-benzodiazepine option
Trazodone or doxepin low dose options depending on setting
Avoid new benzodiazepine initiation in most cases
Restlessness and akathisia like symptoms
Gabapentin use varies by local policy
Misuse potential counselling
Autonomic symptoms
Alpha-2 agonist adjunct
Cooling measures for diaphoresis
Treatments to avoid or use with caution
Ultra-rapid opioid detoxification with anesthesia
Not recommended due to high risk of adverse events and death
Opioid agonist plus sedatives without monitoring
Increased respiratory depression risk
Antidiarrheals masking infection
Fever or bloody stool as red flags
Special Populations
Pregnancy
Maternal fetal considerations
Untreated withdrawal associated with relapse risk and physiologic stress
Medication for OUD preferred over detoxification in most cases
Medication selection
Methadone and buprenorphine as standard options in guidelines
Coordination with obstetrics and addiction care
Avoid naltrexone initiation during acute withdrawal in pregnancy
Induction considerations
Close monitoring during initiation
Volume status
Fetal assessment when viable gestation
Breastfeeding considerations
Buprenorphine and methadone compatible in many cases
Individualized assessment and counselling
Geriatric
Physiologic risks
Higher sensitivity to hypotension
Alpha-2 agonist dose caution
Higher fall risk with sedation
Avoid polypharmacy
Comorbidity burden
Cardiac conduction disease
ECG consideration with methadone or lofexidine
Renal impairment
Lofexidine dose reduction based on eGFR
Disposition bias
Lower threshold for observation or admission when frail
Pediatrics
Scope note
Most opioid withdrawal management guidance applies to adolescents and adults
Neonatal abstinence syndrome is separate pathway
Adolescent considerations
Confidentiality and consent laws vary by jurisdiction
Family involvement when safe and appropriate
Medication safety
Lofexidine safety not established in children per prescribing information
Buprenorphine use follows local regulatory approvals and specialist guidance
Background
Epidemiology
Opioid withdrawal context
Withdrawal occurs in opioid dependence after reduction or cessation
Fentanyl era increases complexity of induction timing and precipitated withdrawal risk
OUD burden
High morbidity and mortality from overdose
Medication for OUD reduces mortality and improves retention
Pathophysiology
Neuroadaptation
Chronic opioid exposure downregulates endogenous opioid tone
Locus coeruleus adrenergic hyperactivity during withdrawal
Clinical manifestations
Autonomic hyperactivity
Sweating
Tachycardia
Hypertension
GI hypermotility
Diarrhoea
Cramping
Central symptoms
Anxiety
Insomnia
Precipitated withdrawal mechanism
Buprenorphine high receptor affinity displaces full agonist
Rapid net decrease in agonism triggers abrupt symptoms
Therapeutic Considerations
Opioid agonist therapy rationale
Buprenorphine partial agonism suppresses withdrawal and cravings
Methadone full agonism suppresses withdrawal and cravings
Alpha-2 agonist rationale
Reduces adrenergic symptoms
Does not treat cravings or OUD core pathology
Outcome considerations
Detoxification without ongoing MOUD associated with high relapse and overdose risk
Reduced tolerance after abstinence increases overdose risk if return to use
Patient Discharge Instructions
copy discharge instructions
Key messages
Reduced tolerance after withdrawal increases overdose risk
Avoid using alone
Avoid mixing opioids with alcohol or benzodiazepines
Medication instructions
Buprenorphine dosing plan
Daily dose schedule provided
Missed dose instructions provided
Symptom medications
Antiemetic plan
Antidiarrheal plan with red flags
Naloxone and overdose response
Naloxone kit provided or prescription arranged
Overdose signs
Slow or stopped breathing
Blue lips or nails
Cannot wake up
Emergency response
Call emergency services immediately
Rescue breathing if trained
Return to ED now
Chest pain
Trouble breathing
Fainting or severe dizziness
Confusion or severe drowsiness
Persistent vomiting with inability to keep fluids down
Fever
Severe abdominal pain
Signs of skin infection
Spreading redness
Pus
Follow-up plan
Addiction medicine clinic appointment details
Primary care follow-up within 1 week
Local support resources contact information
References
Clinical guidelines and key sources
ASAM National Practice Guideline for the Treatment of Opioid Use Disorder 2020 Focused Update
Buprenorphine initiation after objective signs of withdrawal
Initial buprenorphine 2-4 mg with titration in 2-8 mg increments
Alpha-2 agonists effective but less effective than buprenorphine or methadone for retention
Ultra-rapid opioid detoxification not recommended due to adverse events and death risk
SAMHSA TIP 63 Medications for Opioid Use Disorder 2021
MOUD as evidence-based standard for OUD
Pregnancy and parenting considerations
Clinical Opiate Withdrawal Scale COWS Wesson and Ling 2003 tool and derivatives
Severity thresholds 5-12 mild 13-24 moderate 25-36 moderately severe more than 36 severe
Lofexidine tablets prescribing information 2024
Starting dosage 0.54 mg orally four times daily
Maximum total daily dose 2.88 mg
Dose adjustment for hepatic and renal impairment
QT prolongation and hypotension warnings
Canadian guidance resources
CRISM National Opioid Use Disorder Guideline November 2024
Health Canada substance use help and referral resources updated 2025
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.